Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 15/20 | 0.59 |
| ▸ | ERBB2 | P04626 | 4/20 | 0.43 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.42 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.42 |
| ▸ | ROS1 | P08922 | 1/20 | 0.42 |
| ▸ | FLT3 | P36888 | 1/20 | 0.42 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.42 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.42 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.42 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.42 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.42 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.42 |
| ▸ | GRM5 | P41594 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30167169 | 0.89 | EGFR (0.63) | EGFRERBB2CHEK2ROS1FLT3 | |
| SCHEMBL30167239 | 0.89 | EGFR (0.61) | EGFRERBB2CHEK2ROS1FLT3 | |
| SCHEMBL30167205 | 0.89 | EGFR (0.60) | EGFRERBB2CHEK2ROS1FLT3 | |
| SCHEMBL30167186 | 0.88 | EGFR (0.61) | EGFRERBB2CHEK2ROS1FLT3 | |
| SCHEMBL30167232 | 0.88 | EGFR (0.59) | EGFRERBB2CHEK2ROS1FLT3 | |
| SCHEMBL30167222 | 0.86 | EGFR (0.75) | EGFRERBB2CHEK2ROS1FLT3 | |
| SCHEMBL30167224 | 0.85 | EGFR (0.58) | EGFRERBB2CHEK2ROS1FLT3 | |
| SCHEMBL30167253 | 0.85 | EGFR (0.59) | EGFRERBB2CHEK2ROS1FLT3 | |
| SCHEMBL30167128 | 0.83 | EGFR (0.62) | EGFRERBB2CHEK2ROS1FLT3 | |
| SCHEMBL30167133 | 0.83 | EGFR (0.57) | EGFRERBB2CHEK2ROS1FLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11548900-B2 | Oxazino-quinazoline and oxazino-quinoline type compound, preparation method and uses thereof | BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED (CN) | 2023-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11548900-B2 | Oxazino-quinazoline and oxazino-quinoline type compound, preparation method and uses thereof | WNK1, WNK2, WNK3 | EGFR 3163/4885ERBB2 912/4885SGMS2 4549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.